Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | HRH1 | P35367 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506775 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3446899 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL30274683 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL609998 | 1.00 | MEN1 (0.61) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11154395 | 0.92 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904230 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904231 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Acetylcarnitine SCHEMBL10904288 | 0.88 | MEN1 (0.81) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL2506515 | 0.86 | LMNA (0.58) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Zinc Ion SCHEMBL7626187 | 0.86 | LMNA (0.58) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | claimed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | claimed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | claimed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| CN-106604725-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2017-04-26 | — | — | CN | claimed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | claimed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | claimed |
| CN-101120935-A | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-02-13 | — | — | CN | claimed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | claimed |
| US-20070072910-A1 | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | NEXGEN PHARMA, INC. | 2007-03-29 | — | — | US | claimed |
| CN-1706814-A | Ultrafine-l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-12-14 | — | — | CN | claimed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | claimed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GARCÍA SADA, FERNANDO (MX) | 2024-11-14 | — | — | US | disclosed |
| EP-4393486-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2024-07-03 | — | — | EP | disclosed |
| CN-118159260-A | Compositions and methods for preventing or reducing the risk of metabolic syndrome | 费尔南多·加西亚·萨达 | 2024-06-07 | — | — | CN | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230210127-A1 | Nutritional Additive for a Tea Drink | Digital Health Solutions Inc (BB) | 2023-07-06 | — | — | US | disclosed |
| CN-116261457-A | Film coated tablet for preventing and treating liver diseases | 赛特瑞恩制药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023027570-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING THE RISK OF METABOLIC SYNDROME | GARCÍA SADA, FERNANDO (MX) | 2023-03-02 | — | — | WO | disclosed |
| US-20230040159-A1 | Nutritional Additive for a Coffee Drink | Digital Health Solutions Inc (BB) | 2023-02-09 | — | — | US | disclosed |
| CN-111132665-B | Pharmaceutical composition and preparation method thereof | 赛特瑞恩制药股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022019578-A1 | FILM-COATED TABLET FOR PREVENTION AND TREATMENT OF LIVER DISEASE | 주식회사 셀트리온제약 | 2022-01-27 | — | — | WO | disclosed |
| CN-113387836-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-106604725-B | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | disclosed |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | NAN Global, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| CN-111803524-A | Oral pharmaceutical composition | 来必制药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111132665-A | Pharmaceutical composition and preparation method thereof | 赛特瑞恩制药股份有限公司 | 2020-05-08 | — | — | CN | disclosed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | disclosed |
| CN-106604725-A | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, or treating or preventing the development of diabetes | NAN全球有限责任公司 | 2017-04-26 | — | — | CN | disclosed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-7851142-B2 | improves/extends period of viability of packed red blood cells and platelet concentrations; improves circulation half life upon transfusion | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-12-14 | — | — | US | disclosed |
| US-7816073-B2 | Method for inhibiting bacterial growth in a leuko-reduced platelet concentrate by adding L-carnitine | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-10-19 | — | — | US | disclosed |
| US-20090092733-A1 | Compositions for Food or Beverage with Improved Hygroscopicity | SUNTORY LIMITED (JP) | 2009-04-09 | — | — | US | disclosed |
| CN-101400270-A | Composition for food and drink with improved hygroscopicity | SUNTORY LTD (JP) | 2009-04-01 | — | — | CN | disclosed |
| EP-1218001-B1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-12-31 | — | — | EP | disclosed |
| EP-2008531-A1 | COMPOSITION FOR FOODS AND DRINKS HAVING IMPROVED HYGROSCOPICITY | Suntory Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| CN-101120935-A | Ultrafine l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2008-02-13 | — | — | CN | disclosed |
| US-7303765-B2 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2007-12-04 | — | — | US | disclosed |
| US-20070248941-A1 | improves/extends period of viability of packed red blood cells and platelet concentrations; improves circulation half life upon transfusion | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-10-25 | — | — | US | disclosed |
| US-20070072910-A1 | Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans | NEXGEN PHARMA, INC. | 2007-03-29 | — | — | US | disclosed |
| CN-1706814-A | Ultrafine-l-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-12-14 | — | — | CN | disclosed |
| US-20050124558-A1 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2005-06-09 | — | — | US | disclosed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | disclosed |
| CN-1177807-C | Stable, non-hygroscopic salts of L carnitine and alkanoyl L carnitines, process for their preparation and solid oral compositions containing them | ϣ��������ҩ��ҵ��˾ | 2004-12-01 | — | — | CN | disclosed |
| US-20040146846-A1 | Storage and maintenance of blood products including red blood cells and platelets | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-07-29 | — | — | US | disclosed |
| EP-1187530-B1 | IMPROVED STORAGE AND MAINTENANCE OF BLOOD PRODUCTS INCLUDING RED BLOOD CELLS AND PLATELETS | SIGMA TAU IND FARMACEUTI (IT) | 2003-09-17 | — | — | EP | disclosed |
| CN-1399549-A | Ultra-fine L-carnitine, methods of making, compositions containing, and methods of using | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2003-02-26 | — | — | CN | disclosed |
| US-20020111383-A1 | Ultrafine L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same | SIGMA-TAU HEALTHSCIENCE S.P.A. (IT) | 2002-08-15 | — | — | US | disclosed |
| US-20020102529-A1 | Recovering and storing blood for use in transfusion; obtain blood, insert into solution tube, irradiate and recover blood cell products | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-08-01 | — | — | US | disclosed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | disclosed |
| CN-1244191-A | Stable, non-hygroscopic salts of L carnitine and alkanoyl L carnitines, process for their preparation and solid oral compositions containing them | CIGMATO PHARMACEUTICAL S P A (IT) | 2000-02-09 | — | — | CN | disclosed |
| CN-1244191-A | Stable, non-hygroscopic salts of L carnitine and alkanoyl L carnitines, process for their preparation and solid oral compositions containing them | CIGMATO PHARMACEUTICAL S P A (IT) | 2000-02-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
| US-20240374552-A1 | Compositions and Methods for Preventing or Reducing the Risk of Metabolic Syndrome | GPR119, GPR27, PTPN7 | MEN1 2509/4885KMT2A 3093/4885CYP1A2 4523/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | GPR119, CPT1B, CPT2 | MEN1 3979/4885KMT2A 1054/4885CYP1A2 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.